HIV

5 Things Gilead Sciences' Management Just Said That You'll Want to Know
5 Things Gilead Sciences' Management Just Said That You'll Want to Know
Motley Fool
Gilead Sciences
Kite Pharma
HIV
hepatitis C
M&A
Flag link:
AIDS activists urge N.Y. attorney general to probe Gilead for antitrust violations
AIDS activists urge N.Y. attorney general to probe Gilead for antitrust violations
Stat
Gilead Sciences
Truvada
antitrust
AIDS
HIV
Flag link:
Gilead circles February 12 on its calendar as D-day for its HIV franchise
Gilead circles February 12 on its calendar as D-day for its HIV franchise
Endpoints
Gilead Sciences
HIV
FTC/TAF
FDA
Flag link:
Bristol-Myers Squibb nixes 58 marketing jobs as HIV medications near patent cliff
Bristol-Myers Squibb nixes 58 marketing jobs as HIV medications near patent cliff
Fierce Pharma
Bristol-Myers Squibb
HIV
layoffs
patent cliff
Reyataz
Sustiva
Flag link:
5 Things Gilead Sciences' Q2 Earnings Numbers Didn't Tell You
5 Things Gilead Sciences' Q2 Earnings Numbers Didn't Tell You
Motley Fool
Gilead Sciences
earnings
hepatitis C
HIV
M&A
Flag link:
J&J reports positive results for HIV regimen
J&J reports positive results for HIV regimen
BioPharma Dive
JNJ
HIV
Gilead Sciences
Darunavir
Flag link:
Gilead's combo shows no resistance in HIV
Gilead's combo shows no resistance in HIV
BioPharma Dive
HIV
Gilead Sciences
emtricitabine/tenofovir alafenamide
Flag link:
J&J touts first-in-human data for HIV vaccine
J&J touts first-in-human data for HIV vaccine
Drug Delivery Business News
JNJ
HIV
vaccines
Janssen
Flag link:
Gilead details its case for a new HIV flagship triple, with megablockbuster potential
Gilead details its case for a new HIV flagship triple, with megablockbuster potential
Endpoints
Gilead Sciences
HIV
bictegravir
FTC/TAF
Flag link:
Gilead faces revived lawsuit claiming it sidestepped FDA with HIV drug imports
Gilead faces revived lawsuit claiming it sidestepped FDA with HIV drug imports
Fierce Pharma
Gilead Sciences
FDA
HIV
whistleblower lawsuits
Flag link:
Can Merck knock Glaxo off its HIV perch? Maybe so, one analyst says
Can Merck knock Glaxo off its HIV perch? Maybe so, one analyst says
Fierce Pharma
Merck
GSK
HIV
ViiV
EFdA
Flag link:
Janssen gets EU nod for continuous manufacturing
Janssen gets EU nod for continuous manufacturing
BioPharma Dive
Janssen
Europe
drug manufacturing
Prezista
HIV
Flag link:
FDA approves Teva's generic copy of Truvada
FDA approves Teva's generic copy of Truvada
BioPharma Dive
FDA
Teva Pharmaceutical
generics
Truvada
HIV
Gilead Sciences
Flag link:
GSK uses priority voucher to file HIV combo
GSK uses priority voucher to file HIV combo
BioPharma Dive
GSK
priority review
HIV
ViiV
Flag link:
ViiV, GSK gamble a surprise $130M chip in a high-stakes HIV playoff with Gilead
ViiV, GSK gamble a surprise $130M chip in a high-stakes HIV playoff with Gilead
Endpoints
GSK
ViiV
HIV
Flag link:
Gilead racing to FDA with a new HIV cocktail boasting megablockbuster potential
Gilead racing to FDA with a new HIV cocktail boasting megablockbuster potential
Endpoints
Gilead Sciences
FDA
HIV
FTC/TAF
Flag link:
Gilead needs to best Glaxo with bictegravir
Gilead needs to best Glaxo with bictegravir
EP Vantage
Gilead Sciences
GSK
bictegravir
Dolutegravir
HIV
Flag link:
The Worst-Case Scenario for Gilead Sciences, Inc.
The Worst-Case Scenario for Gilead Sciences, Inc.
Motley Fool
Gilead Sciences
M&A
hepatitis C
HIV
Flag link:
Here's Why the Best Is Yet to Come for Gilead Sciences, Inc.
Here's Why the Best Is Yet to Come for Gilead Sciences, Inc.
Motley Fool
Gilead Sciences
HIV
hepatitis C
Flag link:
Napo amps up sales force for AIDS anti-diarrheal
Napo amps up sales force for AIDS anti-diarrheal
BioPharma Dive
Napo
drug reps
AIDS
HIV
Mytesi
Alamo Pharma Services
Flag link: